President, Chief Executive Officer, Chair of the Board, Organogenesis Holdings
Search every verified Gary Gillheeney interview, podcast appearance, and on-the-record quote — each transcript cross-checked by AI and human review to confirm speaker identity. In a September 2024 interview, Gary Gillheeney stated that Organogenesis has grown annual revenues by nearly 400% to about $400 million and more than doubled its employee base to approximately 900, achieving profitability in 2020. He described the company's mission as providing solutions that improve lives while lowering the overall cost of care, and said its portfolio addresses every type of chronic wound in all sites of care except third-degree burns. Gillheeney noted that chronic wounds affect over 7 million Americans annually and that, if left untreated, as many as 30% of these wounds can result in amputation, citing a five-year post-amputation mortality rate of 50%. Gillheeney said the company has lobbied CMS and congressional delegations about proposed Medicare payment methodologies for skin substitutes, expressing concern that the changes could affect patient access and potentially lead to avoidable amputations and exacerbate health inequities. He highlighted that disparities in social determinants of health have a profound impact on wound healing, with amputations being substantially more prevalent in racial and ethnic minority populations. Gillheeney also discussed the company's pipeline product "RENEW," which he described as designed to address unmet medical needs in osteoarthritis, a market affecting more than 30 million Americans.
“We've grown annual revenues by nearly 400% to about 400 million at about a 30% CAGR and more than doubled our employee base to approximately 900, achieving profitability in 2020 well ahead of Street expectations.”
“Our mission is to provide solutions that improve lives while lowering the overall cost of care, and over the next 10 years we will continue to pursue innovations that improve lives and advance the science while delivering sustainable value to the healthcare system.”
“Chronic wounds affect over 7 million Americans annually and are often associated with comorbidities like diabetes and cardiovascular disease; if left untreated, as many as 30% of these wounds will result in an amputation, which is devastating for both patients and the healthcare system.”
“The five-year post-amputation mortality rate is 50%, which is higher than the five-year mortality rate for all cancers combined, underscoring that chronic wounds are a medical emergency that needs to be treated.”
In this episode, we sit down with Gary Gillheeney, Sr., President & CEO of Organogenesis, the Canton, Massachusetts-based ...
Sign in to search the full transcript archive, filter by topic, and access every quote from Gary Gillheeney.